Analytical Data
-
Gene name
Siglec-5
- Application
-
Alternative Names
CD170; CD33L2; OB-BP2; OBBP2; CD33 antigen-like 2; Obesity-binding protein 2; OB-binding protein 2
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
O15389
-
Expression Region
Lys18~Leu135
-
Molecular Weight
20kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Siglec-5, a member of the SIGLEC (Sialic Acid Binding Ig-like Lectin) family, plays a crucial role in the immune system by modulating the activity of immune cells through its interaction with sialic acid, a common carbohydrate found on the surface of many cells. Research has indicated that Siglec-5 is primarily expressed on immune cells such as macrophages and dendritic cells, where it functions as an inhibitory receptor, dampening the immune response and thus contributing to the maintenance of immune tolerance. Its implications in various diseases, including autoimmune disorders and infections, have garnered significant attention in immunology. Studies have focused on the potential of Siglec-5 as a therapeutic target, investigating how modulation of its activity could enhance anti-tumor immunity or improve responses to vaccines. The engineering of Siglec-5 recombinant proteins has emerged as a promising avenue for understanding its biological functions and developing novel immunotherapeutic strategies. By producing these recombinant proteins, researchers aim to dissect the molecular mechanisms underlying Siglec-5's immunological roles and explore its potential utility in clinical applications, particularly in controlling inflammatory diseases and enhancing immune responses. Overall, the study of Siglec-5 and its recombinant forms represents a significant step towards harnessing the body's innate immune functions in the fight against diseases.
